The Transurban Group (ASX: TCL) share price is in focus today after announcing a major expansion to its North American operations, including a proposed 140% capacity boost for the I-95 Express Lanes.

What did Transurban report?

• Entered a Development Framework Agreement for enhanced Bi-Directional Project on I-95 Express Lanes in Virginia
• Transurban holds 50% indirect interest in the 95 Express Lanes LLC
• Proposed project scope would add about 120 new lane miles—six times more than previously planned
• 10-mile extension will extend the lanes through Fredericksburg into Spotsylvania County
• Project would increase I-95 Express Lanes capacity by around 140%
• Financial close is targeted for 2029, subject to agreement and approval

What else do investors need to know?

The development marks a major step in Transurban’s North American growth strategy, demonstrating the company’s ability to secure significant infrastructure opportunities in markets it knows well. The collaboration with the Virginia Department of Transportation is expected to bring benefits to both local motorists and Transurban stakeholders.

The next stage will focus on final design work, contractor selection, and confirming capital requirements, ahead of submitting a binding proposal. Transurban anticipates further updates as the project advances, reinforcing its long-term presence and partnerships in the US market.

What did Transurban management say?

Transurban CEO Michelle Jablko said:

Opportunities of this scale in a market we know well, underscore the strength and optionality of Transurban’s North American presence, as we continue to partner with government to deliver transformative infrastructure that drives long-term value for both customers and our investors.

What’s next for Transurban?

With the expanded project scope, Transurban is positioned to play a key role in upgrading one of the region’s most important transport corridors. Management expects the proposed I-95 project to deliver growth potential, customer benefits, and ongoing value for investors.

Transurban will now work on design, contractor engagement, and final cost estimates before progressing to the next stage. If the binding proposal gains approval, financial close is targeted for 2029.

Transurban share price snapshot

Over the past 12 months, Transurban shares have risen 9%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 2% over the same period.

View Original Announcement

The post Transurban Group announces major North America project expansion appeared first on The Motley Fool Australia.

More reading

• Centuria Capital Group opens $35m retail offer, targets growth in AI and real estate
• Ampol launches new $400m subordinated notes facility
• 5 things to watch on the ASX 200 on Friday
• What’s next for BHP shares? Broker forecasts revealed
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Transurban Group. The Motley Fool Australia has positions in and has recommended Transurban Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Ampol Ltd (ASX: ALD) share price is in focus today after the company announced a new A$400 million delayed-draw subordinated notes facility, following successful previous issues in 2025. This new facility supports Ampol’s ongoing capital management and provides flexible, long-term funding options.

What did Ampol report?

• Launched a wholesale offer of a new A$400 million delayed-draw subordinated notes facility
• Facility can be drawn in two tranches: A$250 million and A$150 million
• ~9-month and ~24-month availability periods for the two tranches, respectively
• 12-year non-call period and a final maturity in 2058
• Net proceeds earmarked to refinance existing subordinated notes callable in 2027 and 2028
• Facility fully underwritten by a cornerstone institutional investor group

What else do investors need to know?

The delayed-draw feature means Ampol can access funding flexibly as needed, with the option to issue the facility in two parts and the right to cancel the second tranche if desired. The subordinated notes are structured to secure long-term capital at fixed pricing, supporting stability in Ampol’s future refinancing plans.

Moody’s Investors Service is expected to assign 50% equity credit to the new notes, in line with Ampol’s existing subordinated debt. The offer is targeted only at institutional investors, with a closing date around 9 July 2026, subject to typical conditions.

What did Ampol management say?

Group Chief Financial Officer Greg Barnes said:

We’re delighted to announce this new financing facility, which utilises the same delayed-draw feature from our previous issue in December 2025. Investor commitments and issue pricing will be fixed upfront. Market conditions remain attractive and provide an opportune time to secure long-term capital, which is linked to our future hybrid refinancing initiatives. The delayed-draw feature gives Ampol significant flexibility with regards to issue timing, as well as use of proceeds and cancellation rights. The transaction is another example of our proactive approach to capital management.

What’s next for Ampol?

Ampol plans to use the facility to proactively refinance subordinated notes due in 2027 and 2028, aiming to optimise its balance sheet and preserve flexibility for future funding needs. Management is focused on securing stable, long-term capital to support its ongoing growth and sustainability initiatives, while enhancing its capital management strategy.

Ampol share price snapshot

Over the past 12 months, Ampol shares have risen 29%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 2% over the same period.

View Original Announcement

The post Ampol launches new $400m subordinated notes facility appeared first on The Motley Fool Australia.

More reading

• Centuria Capital Group opens $35m retail offer, targets growth in AI and real estate
• Transurban Group announces major North America project expansion
• 5 things to watch on the ASX 200 on Friday
• What’s next for BHP shares? Broker forecasts revealed
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

It has been another big day for 4DMedical Ltd (ASX: 4DX) shareholders.

The ASX 200 healthcare stock is pushing higher on Friday after releasing an update that has kept investors interested.

At the time of writing, the 4DMedical share price is up 8.75% to $4.97.

The stock is now up around 40% over the past month and an incredible 1,800% since this time last year.

Here’s what 4DMedical announced to the market.

4DMedical gets TGA approval

According to the release, 4DMedical has received approval from the Therapeutic Goods Administration (TGA) for its CT:VQ product in Australia.

This means CT:VQ has now been included on the Australian Register of Therapeutic Goods, allowing it to be sold commercially across the country.

The company said CT:VQ is the world’s first non-contrast, CT-based ventilation-perfusion imaging solution.

The software helps doctors see how air and blood move through the lungs using standard CT scans. Essentially, patients can be assessed without the need for some nuclear medicine imaging methods.

4DMedical said the approval could support use across metropolitan, regional, and rural Australia, including areas with CT scanners but limited access to nuclear medicine services.

The company noted that CT:VQ is already approved in several major markets, including the US, Europe, the UK, Canada, and New Zealand.

What investors will be watching now

The approval gives 4DMedical a new market to work with, but investors will want to see how quickly that turns into adoption.

Although, there’s already some progress overseas.

In the United States, CT:VQ has been deployed at major clinical sites including Stanford, Cleveland Clinic, and the University of Miami.

The company has also signed an agreement with SimonMed Imaging, one of the largest outpatient radiology providers in the United States.

Back in Australia, the next step for the company is reimbursement.

Management said it is preparing an application to the Medical Services Advisory Committee to seek future Medicare Benefits Schedule reimbursement for CT.

If that’s approved, it could make the product much easier to be used more widely across our healthcare system.

Can the rally keep going?

Without doubt, the approval is a positive milestone.

But after rocketing 1,800% in 12 months, this isn’t a small company anymore flying under the radar.

4DMedical has a market capitalisation of around $2.8 billion, which means investors are already pricing in a much larger business.

And while that doesn’t mean the rally has gone too far, it certainly does raise the bar.

For now, the company needs to keep showing that CT can move from approvals and trial sites into broader commercial use.

The post This ASX 200 stock has soared 1,800%. Is there more to come? appeared first on The Motley Fool Australia.

More reading

• This ASX healthcare stock is up 1,900%. One top fundie wants more
• Up 1,700% and more, what’s next for these ASX 200 shares?
• Here are the top 10 ASX 200 shares today
• Here are the 10 most shorted ASX shares
• Healthcare shares led the ASX 200 last week. Is a sector comeback underway?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.